Thursday, February 12, 2015 10:10:21 AM
February 12th, 2015 •
Cancer Genetics logoCancer Genetics (NASDAQ:CGIX) has received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus target price of $14.38 for the company and are forecasting that the company will post ($0.48) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Cancer Genetics an industry rank of 65 out of 265 based on the ratings given to related companies.
Cancer Genetics (NASDAQ:CGIX) opened at 6.99 on Thursday. Cancer Genetics has a 52-week low of $4.83 and a 52-week high of $20.95. The stock’s 50-day moving average is $7.52 and its 200-day moving average is $7.7. The company’s market cap is $68.0 million.
Cancer Genetics (NASDAQ:CGIX) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.10. On average, analysts predict that Cancer Genetics will post $-1.73 earnings per share for the current fiscal year.
Cancer Genetics, Inc (NASDAQ:CGIX) is an early-stage, diagnostic company. The Company focuses on developing and commercializing genomic tests and services to improve the diagnosis, prognosis and response to treatment (theranosis) of cancer.
To get a free copy of the research report on Cancer Genetics (CGIX), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com
__________________________________________
http://www.americanbankingnews.com/2015/02/12/analysts-expect-cancer-genetics-to-announce-0-48-eps-nasdaqcgix/
CGIX
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM